Suloctidil hepatitis: A case presentation

Kelly, Ciarán P.; England, Rebecca; McDonald, G. S. A.; Weir, Donald G.

doi:10.1007/bf02954074

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the concentration of suloctidil tested in highly efficacious combinations in liquid (16 μM) was twice as concentrated as previously reported maximal plasma concentrations and equal to reported cytotoxic levels in RAW264.7 mouse macrophage cells and C32 human melanoma cells, warranting further testing of lower concentrations of suloctidil in combination with other hits. 30 , 32 , 33 , 42 − 45 While suloctidil’s hepatotoxic effects caused its removal from the market from its original indication of vasodilation to treat arterial diseases, its potential to treat a dangerously lethal infection such as anthrax and its possibility of efficacy at lower concentrations than previously indicated suggest a potential future against B. anthracis .…”

Section: Resultsmentioning

confidence: 99%

Repurposing Clinically Approved Drugs for the Treatment of Bacillus cereus, a Surrogate for Bacillus anthracis

et al. 2020

View full text Add to dashboard Cite

Of the numerous infectious diseases afflicting humans, anthrax disease, caused by Bacillus anthracis , poses a major threat in its virulence and lack of effective treatment. The currently lacking standards of care, as well as the lengthy drug approval process, demonstrate the pressing demand for treatment for B. anthracis infections. The present study screened 1586 clinically approved drugs in an attempt to identify repurposable compounds against B. cereus , a relative strain that shares many physical and genetic characteristics with B. anthracis . Our study yielded five drugs that successfully inhibited B. cereus growth: dichlorophen, oxiconazole, suloctidil, bithionol, and hexestrol. These drugs exhibited varying levels of efficacy in broad-spectrum experiments against several Gram-positive and Gram-negative bacterial strains, with hexestrol showing the greatest inhibition across all tested strains. Through tests for the efficacy of each drug on B. cereus , bithionol was the single most potent compound on both solid and liquid media and exhibited even greater eradication of B. cereus in combination with suloctidil on solid agar. This multifaceted in vitro study of approved drugs demonstrates the potential to repurpose these drugs as treatments for anthrax disease in a time-efficient manner to address a global health need.

show abstract